ArticleKidney international reports2022
Platelet Activity and Cardiovascular Risk in CKD and Peripheral Artery Disease.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- A platelet-monocyte pyroptotic axis mediates uremic cardiomyopathy: critical role of PF4 and hematopoietic caspase-1.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Article
- Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming.Blood advances · 2026Article
- The relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.Renal failure · 2025Article
- Systemic immune inflammation index and all-cause mortality in chronic kidney disease: A prospective cohort study.Immunity, inflammation and disease · 2024Article
- Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients.International journal of molecular sciences · 2024Review
- Mediation effect of antithrombin III between chronic renal insufficiency and chronic coronary artery disease in T2DM patients.Endocrine · 2024Article
- Association of mixed polycyclic aromatic hydrocarbons exposure with cardiovascular disease and the mediating role of inflammatory indices in US adults.Environmental health and preventive medicine · 2024Article
- CKD Effects on Platelets: Implications for Cardiovascular Risk.Kidney international reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Introduction: Platelet dysfunction and cardiovascular risk are well-recognized features of chronic kidney disease (CKD). Platelets drive the development and progression of cardiovascular disease (CVD). The relationships between kidney function, platelet activity, and cardiovascular risk are poorly defined. Methods: We compared platelet activity and incident cardiovascular events by CKD status (estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m Results: Overall, 113 of 285 (40%) subjects had CKD. Subjects with, versus without, CKD had higher platelet aggregation in response to stimulation with adenosine diphosphate (ADP), serotonin, epinephrine, and arachidonic acid (AA) + Conclusion: Among subjects with PAD undergoing lower extremity revascularization, CKD is associated with increased platelet activity that mediates, in part, elevated cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.